KAON CL-10
Clinical safety rating
cautionComprehensive clinical and safety monograph for KAON CL-10 (KAON CL-10).
Potassium supplement to treat or prevent hypokalemia; potassium is the major intracellular cation essential for nerve transmission, muscle contraction, and acid-base balance.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys; metabolism is not significant. |
| Excretion | Primarily renal elimination (>90% as unchanged drug); minor biliary/fecal excretion (<5%). Excretion is via glomerular filtration and tubular reabsorption; potassium excretion is influenced by aldosterone and acid-base status. |
| Half-life | Terminal elimination half-life is approximately 3-5 hours in healthy adults, reflecting rapid equilibration with the total body potassium pool. Clinically, the half-life is not directly applicable due to extensive intracellular distribution; steady-state is achieved within 24-48 hours. |
| Protein binding | Potassium is not significantly protein-bound; <5% bound to plasma proteins. |
| Volume of Distribution | Approximately 0.5 L/kg, representing distribution primarily into intracellular fluid (98% of total body potassium is intracellular). Clinical meaning: Low Vd indicates limited distribution to extracellular space; high intracellular uptake requires careful dosing to avoid hyperkalemia. |
| Bioavailability | Oral: >90% absorbed via passive diffusion along the gastrointestinal tract. Intravenous: 100% bioavailability. |
| Onset of Action | Oral: 30-60 minutes for elevation of serum potassium; intravenous administration yields immediate effect (within minutes). |
| Duration of Action | Oral: Duration of effect on serum potassium is approximately 6-8 hours, but may persist longer with high doses or impaired excretion. Continuous replacement is needed for maintenance. |
| Molecular Weight | 74.55 |
Oral: 20 mEq (2 tablets) 2-4 times daily with meals; maximum 100 mEq/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25%; GFR 10-29 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use. |
| Pediatric use | Oral: 1-3 mEq/kg/day in divided doses, maximum 3 mEq/kg/day; not recommended for children <1 year. |
| Geriatric use | Start at lowest dose (10 mEq twice daily); monitor renal function and potassium levels; avoid doses exceeding 40 mEq/day. |
| 1st trimester | No evidence of harm in animal studies; insufficient human data. Use only if clearly needed. |
| 2nd trimester | No known risks; monitor serum potassium levels. |
| 3rd trimester | May be used for potassium depletion; avoid excessive doses causing hyperkalemia. |
Clinical note
Comprehensive clinical and safety monograph for KAON CL-10 (KAON CL-10).
| Placental transfer | Potassium crosses the placenta by active transport; fetal serum levels are similar to maternal levels. |
| Breastfeeding | Potassium chloride is a normal constituent of breast milk. Supplementation is generally considered compatible with breastfeeding; monitor infant for hyperkalemia if maternal doses are high. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride (the active ingredient in Kaon CL-10) is not associated with teratogenic risk in any trimester. No fetal malformations or developmental toxicity have been reported. Hypokalemia itself may pose maternal and fetal risks, but the drug does not have intrinsic teratogenic potential. |
| Fetal Monitoring | Monitor serum potassium levels frequently, especially if combined with potassium-sparing diuretics or in renal impairment. Monitor maternal ECG if hyperkalemia suspected. No specific fetal monitoring required beyond routine prenatal care. |
| Fertility Effects | No adverse effects on fertility have been reported. Potassium chloride is a normal electrolyte and does not impair reproductive function. |
■ FDA Black Box Warning
Warning: Potassium chloride can cause hyperkalemia and cardiac arrest if given too rapidly or in excessive doses. Avoid in patients with severe renal impairment, adrenal insufficiency, or concurrent use of potassium-sparing diuretics.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or azotemiaUntreated Addison's diseaseAcute dehydrationHeat crampsSolid dosage forms in patients with delayed gastrointestinal transit
| Precautions | Monitor serum potassium levels and renal function; avoid high doses or rapid infusion; use with caution in patients with cardiac disease or receiving digitalis; gastrointestinal irritation may occur with oral preparations. |
| Food/Dietary | Avoid salt substitutes and low-sodium products that contain potassium chloride. No specific food restrictions beyond ensuring adequate water intake with each dose to prevent esophageal or gastric irritation. |
| Clinical Pearls | Kaon CL-10 is a solid oral dosage form of potassium chloride (KCl) 10 mEq. Do not split or crush tablets; they must be swallowed whole with a full glass of water to reduce GI irritation. Monitor serum potassium, renal function, and ECG. Use with caution in patients with impaired renal function or those on ACE inhibitors, ARBs, or potassium-sparing diuretics. Rapid IV correction is reserved for severe hypokalemia with ECG changes. |
| Patient Advice | Take this medication with food and a full glass of water to prevent stomach upset. · Do not crush, chew, or split the tablet; swallow it whole. · Missing a dose: take it as soon as you remember unless almost time for the next dose; do not double up. · Report symptoms of high potassium: muscle weakness, tiredness, numbness/tingling, irregular heartbeat, or confusion. · Do not use salt substitutes or potassium-containing supplements unless directed by your doctor. |
Loading safety data…